Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020281 | 0.94 | HDAC4 (0.62) | HDAC4HSD11B1ALDH1A1LMNAMAPT | |
| SCHEMBL3406369 | 0.92 | HSD11B1 (0.56) | HDAC4HSD11B1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL652508 | 0.84 | DRD2 (0.56) | HDAC4HSD11B1 | |
| SCHEMBL8353588 | 0.82 | MAPT (0.46) | HDAC4HSD11B1ALDH1A1LMNAMAPT | |
| SCHEMBL3443425 | 0.82 | HDAC4 (0.61) | HDAC4HSD11B1ALDH1A1LMNAFFAR2 | |
| SCHEMBL1794 | 0.82 | AKR1C1 (0.62) | HDAC4HSD11B1ALDH1A1FFAR2HDAC1 | |
| SCHEMBL12104025 | 0.82 | OPRM1 (0.63) | HSD11B1ALDH1A1LMNAMAPT | |
| SCHEMBL10002416 | 0.81 | HDAC4 (0.59) | HDAC4HSD11B1ALDH1A1LMNAFFAR2 | |
| SCHEMBL5635956 | 0.81 | HDAC4 (0.59) | HDAC4HSD11B1ALDH1A1LMNAFFAR2 | |
| SCHEMBL12981104 | 0.81 | HDAC1 (0.47) | HDAC4HSD11B1ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-5047432-A | Antidepressants | THE BOOTS COMPANY PLC (GB) | 1991-09-10 | — | — | US | disclosed |
| US-4925879-A | ANTIDEPRESSANTS | BOOTS COMPANY, PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| US-4814352-A | ANTIDEPRESSANT CYCLOBUTYL BENZYLAMINE | THE BOOTS COMPANY PLC (GB) | 1989-03-21 | — | — | US | disclosed |
| US-4806570-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4767790-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| EP-0191542-B1 | ARYLCYCLOBUTYLALKYL AMINES AND THEIR USE AS ANTIDEPRESSIVE MEDICINES | The Boots Company PLC (GB) | 1988-06-08 | — | — | EP | disclosed |
| US-4746680-A | ANTIDEPRESSANTS | THE BOOTS COMPANY P.L.C. (GB) | 1988-05-24 | — | — | US | disclosed |
| EP-0191542-A1 | Arylcyclobutylalkyl amines and their use as antidepressive medicines | The Boots Company PLC (GB) | 1986-08-20 | — | — | EP | disclosed |
| US-4522828-A | CYCLOBUTYLALKYLAMINE COMPOUNDS, ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| US-4443449-A | Arylcyclobutylalkylamines and anti-depression composition and methods using same | THE BOOTS COMPANY LIMITED (GB) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HSD11B1 4193/4885ALDH1A1 3966/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HSD11B1 4193/4885ALDH1A1 3966/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HDAC4 2750/4885HSD11B1 4193/4885ALDH1A1 3966/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HDAC4 2374/4885HSD11B1 4111/4885ALDH1A1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.